HomeCompareUCBJY vs PLD

UCBJY vs PLD: Dividend Comparison 2026

UCBJY yields 0.52% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.89M in total portfolio value
10 years
UCBJY
UCBJY
● Live price
0.52%
Share price
$150.79
Annual div
$0.79
5Y div CAGR
7.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$111.23
Full UCBJY calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — UCBJY vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUCBJYPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UCBJY + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UCBJY pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UCBJY
Annual income on $10K today (after 15% tax)
$44.56/yr
After 10yr DRIP, annual income (after tax)
$94.55/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,038,021.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UCBJY + PLD for your $10,000?

UCBJY: 50%PLD: 50%
100% PLD50/50100% UCBJY
Portfolio after 10yr
$2.96M
Annual income
$2,375,418.20/yr
Blended yield
80.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

UCBJY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
6.1
Piotroski
8/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UCBJY buys
1
PLD buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$UCBJY▼ Sell$1,001 - $15,0002023-07-10
Daniel Goldman🏢 House$UCBJY▲ Buy$1,001 - $15,0002023-02-27
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUCBJYPLD
Forward yield0.52%3.10%
Annual dividend / share$0.79$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7.3%74.4%
Portfolio after 10y$20.7K$5.91M
Annual income after 10y$111.23$4,750,725.19
Total dividends collected$810.00$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: UCBJY vs PLD ($10,000, DRIP)

YearUCBJY PortfolioUCBJY Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,756$56.25$11,241$540.96$485.00PLD
2$11,570$60.67$13,019$991.13$1.4KPLD
3$12,445$65.44$15,801$1,870.97$3.4KPLD
4$13,387$70.59$20,609$3,701.21$7.2KPLD
5$14,400$76.15$29,919$7,867.97$15.5KPLD
6$15,490$82.14$50,631$18,617.74$35.1KPLD
7$16,663$88.60$105,528$51,352.20$88.9KPLD
8$17,925$95.58$287,364$174,449.42$269.4KPLD
9$19,283$103.11$1,081,760$774,280.77$1.06MPLD
10$20,744$111.23$5,908,209$4,750,725.19$5.89MPLD

UCBJY vs PLD: Complete Analysis 2026

UCBJYStock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Full UCBJY Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this UCBJY vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UCBJY vs SCHDUCBJY vs JEPIUCBJY vs OUCBJY vs KOUCBJY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.